Market open
Jazz Pharmaceuticals/$JAZZ
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Ticker
$JAZZ
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Dublin, Ireland
Employees
2,800
Website
JAZZ Metrics
BasicAdvanced
$8.1B
15.51
$8.65
0.44
-
Price and volume
Market cap
$8.1B
Beta
0.44
52-week high
$148.06
52-week low
$99.06
Average daily volume
935K
Financial strength
Current ratio
4.457
Quick ratio
3.572
Long term debt to equity
149.524
Total debt to equity
150.642
Interest coverage (TTM)
3.62%
Management effectiveness
Return on assets (TTM)
4.60%
Return on equity (TTM)
14.31%
Valuation
Price to earnings (TTM)
15.511
Price to revenue (TTM)
2.039
Price to book
1.99
Price to tangible book (TTM)
-3.42
Price to free cash flow (TTM)
5.943
Growth
Revenue change (TTM)
6.12%
Earnings per share change (TTM)
41.76%
3-year revenue growth (CAGR)
9.56%
3-year earnings per share growth (CAGR)
16.13%
What the Analysts think about JAZZ
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
JAZZ Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
JAZZ Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
JAZZ News
AllArticlesVideos
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
Business Wire·3 days ago
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
Benzinga·1 week ago
Jazz Pharmaceuticals to buy Chimerix for $935 million
Reuters·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Jazz Pharmaceuticals stock?
Jazz Pharmaceuticals (JAZZ) has a market cap of $8.1B as of March 13, 2025.
What is the P/E ratio for Jazz Pharmaceuticals stock?
The price to earnings (P/E) ratio for Jazz Pharmaceuticals (JAZZ) stock is 15.51 as of March 13, 2025.
Does Jazz Pharmaceuticals stock pay dividends?
No, Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders as of March 13, 2025.
When is the next Jazz Pharmaceuticals dividend payment date?
Jazz Pharmaceuticals (JAZZ) stock does not pay dividends to its shareholders.
What is the beta indicator for Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.